课题基金 / 基金详情

ACUTE RENAL GRAFT REJECTION W/ BMY-42215-1 (15-DEOXYSPERGUALIN TRIHYDROCHLORIDE)

ACUTE RENAL GRAFT REJECTION W/ BMY-42215-1 (15-DEOXYSPERGUALIN TRIHYDROCHLORIDE)
BMY-42215-1（15-脱氧精胍菌素三盐酸盐）引起的急性肾移植排斥
批准号：
6244690
负责人：
ALAN B LEICHTMAN
金额：
$2.22万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-20 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244690
关键词：
clinical research combination chemotherapy corticosteroids drug screening /evaluation graft versus host disease guanidines human subject human therapy evaluation immunosuppressive intravenous administration kidney transplantation outcomes research transplant rejection

项目摘要

项目成果

ALAN B LEICHTMAN的其他基金

相似基金

相关文献

中文摘要
翻译
本研究旨在评估BMY-42215-1的疗效和安全性 （脱氧精胍菌素，DSG）加静脉冲击皮质类固醇比较 安慰剂加静脉冲击皮质类固醇治疗 急性肾移植排斥反应患者。 的意图 该研究是为了确定是否添加15-脱氧精胍灵- 糖皮质激素治疗可改善排斥反应的结局 治疗和减少对抗淋巴细胞剂治疗的需要 例如OKT 3或ATGAM。
英文摘要
This study is designed to assess the efficacy and safety of BMY-42215-1 (deoxyspergualin, DSG) plus intravenous pulse corticosteroids compared with placebo plus intravenous pulse corticosteroids in the treatment of patients with acute renal allograft rejection episodes. The intent of the study is to establish whether the addition of 15-deoxyspergualin- trichloride to corticosteroids will improve the outcomes of rejection therapy and reduce the need for treatment with antilymphocyte agents such as OKT3 or ATGAM.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SIROLIMUS AZATHIOPRINE WITH IMMUNOSUPPRESSIVE THERAPY IN ALLOGRAFT RECIPIENTS
SIROLIMUS AZATHIOPRINE WITH IMMUNOSUPPRESSIVE THERAPY IN ALLOGRAFT RECIPIENTS
SIROLIMUS AZATHIOPRINE WITH IMMUNOSUPPRESSIVE THERAPY IN ALLOGRAFT RECIPIENTS
NEORAL (TM) IN STABLE RENAL TRANSPLANT PATIENTS
海外基金